What is the starting dose of semaglutide (4.36 mg/mL) in insulin syringe units and milliliters?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: May 21, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Starting Dose of Semaglutide 4.36 mg/mL

The starting dose of semaglutide at 4.36 mg/mL concentration is 0.25 mg once weekly, which equals approximately 0.06 mL or 6 units on an insulin syringe.

Dose Conversion Calculation

For the 4.36 mg/mL concentration:

  • 0.25 mg dose = 0.057 mL (approximately 0.06 mL)
  • In insulin syringe units: approximately 6 units (since 1 unit = 0.01 mL)

Standard Titration Schedule

The FDA-approved titration schedule 1 begins with 0.25 mg weekly and follows this algorithm:

  • Weeks 1-4: 0.25 mg once weekly (6 units/0.06 mL)
  • Weeks 5-8: 0.5 mg once weekly (12 units/0.11 mL)
  • Weeks 9-12: 1.0 mg once weekly (23 units/0.23 mL)
  • Week 13+: 1.7 mg once weekly (39 units/0.39 mL) for obesity indication
  • Week 17+: 2.4 mg once weekly (55 units/0.55 mL) as maximum maintenance dose

This gradual escalation is critical to minimize gastrointestinal adverse events 2.

Clinical Context

Multiple high-quality guidelines consistently recommend starting at 0.25 mg weekly regardless of indication (diabetes or obesity) 3. The 2025 AACE consensus statement 3 and 2022 AGA guidelines 2 both emphasize that this starting dose is non-negotiable for tolerability.

The initial 0.25 mg dose serves as a lead-in period rather than a therapeutic dose—it primes the patient for higher doses while minimizing nausea, vomiting, and other GI side effects that occur in 40-44% of patients 2. Recent evidence suggests even slower titration may improve adherence: a 2025 RCT 4 found that flexible titration starting at 0.0675 mg (1.5 units) reduced treatment discontinuation from 19% to 2%.

Important Practical Considerations

Never skip the dose escalation schedule. Jumping directly to higher doses dramatically increases GI adverse events and treatment discontinuation 2. If a patient misses doses, clinical judgment determines whether to continue at the same dose (if well-tolerated previously) or step back one dose level 2.

The concentration matters for accurate dosing. The 4.36 mg/mL concentration requires careful measurement—using an insulin syringe marked in units provides the most precise delivery for these small volumes.

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.